Since PSMA expression in solid tumours other than prostate cancer is primarily observed in the tumour neovasculature, and it showed promising performance compared to standard morphological and functional imaging, further studies are needed to assess whether this novel imaging examination might improve oncological patients’ management in specifical clinical settings such as the monitoring of antineoangiogenic therapies. This evidence concerns the gene FOLH1 and prostate carcinoma.